
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion AS has demonstrated a strong position in the neoantigen cancer vaccine space, with the PIONEER AI model achieving an improved prediction accuracy of 81% for identifying immunogenic neoantigens, reinforcing its competitive edge. The clinical outcomes of patients treated with the EVX-01 vaccine in combination with pembrolizumab reflect a promising overall response rate (ORR) of 75%, which exceeds previous data, thus indicating the potential for effective treatment options in oncology. Furthermore, the sustained patient responses and favorable safety profile contribute to a heightened optimism regarding Evaxion's innovative approach to immunotherapy and its ongoing commitment to address significant unmet medical needs in cancer treatment.
Bears say
Evaxion AS's stock has experienced a negative reaction despite the positive data update for its EVX-01 program, primarily due to investor disappointment regarding the lack of a clear signal on the program's potential contribution to the company's financial outlook. This may indicate a gap between market expectations and the company's current capabilities or communication regarding its product pipeline. Additionally, the overall sentiment reflects concerns about the sustainability of the company’s innovative approaches in a competitive biotech landscape, which could hinder investor confidence and impact future funding opportunities.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares